Citius Pharmaceuticals reports first revenue after LYMPHIR launch
Biotech generates $3.9 million from new cancer therapy as it works toward profitability
Citius Pharmaceuticals has reported its first revenue as a publicly traded company, generating $3.9 million from initial US sales of its cancer therapy LYMPHIR, marking a critical milestone in the biotechnology company's transformation from a development-stage business to commercial operations.
The revenue, which exceeded analyst estimates of $3.5 million, came from December 2025 sales of LYMPHIR following its commercial launch in the United States. The therapy, approved by the FDA in August 2024, treats adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL) who have undergone at least one prior systemic therapy. The product achieved an 80% gross margin, according to the company's earnings announcement.
The company reported a net loss of $0.41 per share for the fiscal first quarter ended December 31, 2025, narrowing from a loss of $1.30 per share in the prior-year period. Citius held $7.7 million in cash and cash equivalents as of quarter-end, providing financial flexibility as it scales commercial operations.
Despite the revenue milestone, shares of Citius fell 11.8% to $0.79 in regular trading on Thursday, reflecting ongoing investor concerns about the company's ability to maintain Nasdaq listing requirements. The stock price remains below the $1.00 minimum bid threshold, even though the company regained compliance with Nasdaq's listing standards in July 2025 after implementing a 1-for-25 reverse stock split the previous November.
The commercial launch of LYMPHIR represents a significant step for Citius, which raised approximately $61 million in fiscal year 2025 to fund the product's introduction. LYMPHIR is a novel immunotherapy designed to target the interleukin-2 receptor found on malignant T-cells and regulatory T cells, addressing an unmet need in CTCL treatment. The FDA approval was supported by Phase 3 trial data demonstrating a 36.2% objective response rate.
Analysts project Citius could achieve profitability by 2027, with average revenue forecasts for 2026 reaching $1.35 billion, according to research compiled by Simply Wall St. The company has a low debt-to-equity ratio of 1.3%, reducing financial risk as it builds its commercial infrastructure.
Beyond LYMPHIR, Citius is advancing its pipeline, including Mino-Lok, an antibiotic lock solution that recently met primary and secondary endpoints in a Phase 3 pivotal trial. The therapy is designed to treat patients with catheter-related bloodstream infections, representing another potential revenue stream if approved.
The company's market capitalization stands at approximately $20 million, with analysts maintaining a price target of $6.00 per share—significantly above current trading levels—according to market data. Citius has two buy ratings and one hold rating from covering analysts.
The transition to commercial operations comes at a challenging time for small-cap biotechnology companies, which have faced funding pressures and investor skepticism following the COVID-19 biotech boom. However, Citius's ability to generate revenue within two months of LYMPHIR's launch demonstrates early commercial traction that could help differentiate it from peers still navigating the development stage.
Investors will be watching subsequent quarterly results closely to assess whether the initial revenue momentum can be sustained and whether cash resources will be sufficient to fund operations until the company achieves profitability. The current cash position of $7.7 million provides runway, though the company has indicated it may need to raise additional capital to support ongoing commercial expansion and pipeline development.